Table 3. Patients (Number and %) with low (≤4 number of residual sites with PD≥5mm ≤4), moderate (Number of residual sites with PD≥5mm: 5–8) and high (Number of residual sites with PD≥5mm ≥9) risk for disease progression [69].

Risk categories	Group A N = 26 (PP) N = 27 (ITT)	Group B N = 24 (PP) N = 26 (ITT)	Group C N = 25 (PP) N = 27 (ITT)	A–B Fisher-Test	A–C Fisher-Test	B–C Fisher-Test
ITT (n = 80)
Baseline				-	-	-
≤4 sites PD≥5mm (n/%)	0	0	0
5–8 sites PD≥5mm (n/%)	0	0	0
≥9 sites PD≥5mm (n/%)	30/100	30/100	31/100
3 months				0.001s	0.314	0.053
≤4 sites PD≥5mm (n/%)	2/7.1	15/50	6/21.4
5–8 sites PD≥5mm (n/%)	6/21.4	6/20	6/21.4
≥9 sites PD≥5mm (n/%)	20/71.4	9/30.0	16/57.1
6 months				<0.001s	0.023s	0.036s
≤4 sites PD≥5mm (n/%)	2/6.7	18/66.7	11/35.5
5–8 sites PD≥5mm (n/%)	8/26.7	1/3.7	6/19.4
≥9 sites PD≥5mm (n/%)	20/66.7	8/29.6	14/45.2
12 months				<0.001s	0.091	0.264
≤4 sites PD≥5mm (n/%)	6/21.4	18/72.0	13/48.1
5–8 sites PD≥5mm (n/%)	8/32.1	2/8.0	4/14.8
≥9 sites PD≥5mm (n/%)	13/46.4	5/20.0	10/37.0
PP (n = 75)
Baseline				-	-	-
≤4 sites PD≥5mm (n/%)	0	0	0
5–8 sites PD≥5mm (n/%)	0	0	0
≥9 sites PD≥5mm (n/%)	26/100	24/100	25/100
3 months				0.005 s	0.146	0.262
≤4 sites PD≥5mm (n/%)	2/7.7	11/45.8	6/24.0
5–8 sites PD≥5mm (n/%)	4/15.4	4/16.7	6/24.0
≥9 sites PD≥5mm (n/%)	20/76.9	9/37.5	13/52.0
6 months				<0.001s	0.004s	0.280
≤4 sites PD≥5mm (n/%)	1/3.8	15/62.5	10/40.0
5–8 sites PD≥5mm (n/%)	8/30.8	1/ 4.2	3/ 12.0
≥9 sites PD≥5mm (n/%)	17/65.4	8/33.3	12/48.0
12 months				0.001s	0.120	0.164
≤4 sites PD≥5mm (n/%)	5/19.2	17/70.8	11/44.0
5–8 sites PD≥5mm (n/%)	9/34.6	2/8.3	4/16.0
≥9 sites PD≥5mm (n/%)	12/46.2	5/20.8	10/40.0

ITT: Intention to treat analyses, PP: per protocol analyses, PD: pocked depth, m: months